|
1
|
Arbyn M, Castellsagué X, de Sanjosé S,
Bruni L, Saraiya M, Bray F and Ferlay J: Worldwide burden of
cervical cancer in 2008. Ann Oncol. 22:2675–2686. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012.PubMed/NCBI
|
|
3
|
Su SY, Huang JY, Ho CC and Liaw YP:
Evidence for cervical cancer mortality with screening program in
Taiwan, 1981–2010: Age-period-cohort model. BMC Public Health.
13:132013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen J, Yao D, Li Y, Chen H, He C, Ding N,
Lu Y, Ou T, Zhao S, Li L and Long F: Serum microRNA expression
levels can predict lymph node metastasis in patients with
early-stage cervical squamous cell carcinoma. Int J Mol Med.
32:557–567. 2013.PubMed/NCBI
|
|
5
|
Yee GP, de Souza P and Khachigian LM:
Current and potential treatments for cervical cancer. Curr Cancer
Drug Targets. 13:205–220. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang F, Liu M, Li X and Tang H: MiR-214
reduces cell survival and enhances cisplatin-induced cytotoxicity
via down-regulation of Bcl2l2 in cervical cancer cells. FEBS Lett.
587:488–495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rose PG, Bundy BN, Watkins EB, Thigpen JT,
Deppe G, Maiman MA, Clarke-Pearson DL and Insalaco S: Concurrent
cisplatin-based radiotherapy and chemotherapy for locally advanced
cervical cancer. N Engl J Med. 340:1144–1153. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thomas GM: Improved treatment for cervical
cancer-concurrent chemotherapy and radiotherapy. N Engl J Med.
340:1198–1200. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mayr NA, Huang Z, Wang JZ, Lo SS, Fan JM,
Grecula JC, Sammet S, Sammet CL, Jia G, Zhang J, et al:
Characterizing tumor heterogeneity with functional imaging and
quantifying high-risk tumor volume for early prediction of
treatment outcome: Cervical cancer as a model. Int J Radiat Oncol
Biol Phys. 83:972–979. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kogo R, How C, Chaudary N, Bruce J, Shi W,
Hill RP, Zahedi P, Yip KW and Liu FF: The microRNA-218~Survivin
axis regulates migration, invasion and lymph node metastasis in
cervical cancer. Oncotarget. 6:1090–1100. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Castellsaguè X, Díaz M, de Sanjosè S,
Muñoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS,
Snijders PJ, et al: Worldwide human papillomavirus etiology of
cervical adenocarcinoma and its cofactors: Implications for
screening and prevention. J Natl Cancer Inst. 98:303–315. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Valencia-Sanchez MA, Liu J, Hannon GJ and
Parker R: Control of translation and mRNA degradation by miRNAs and
siRNAs. Genes Dev. 20:515–524. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Winter J, Jung S, Keller S, Gregory RI and
Diederichs S: Many roads to maturity: Microrna biogenesis pathways
and their regulation. Nat Cell Biol. 11:228–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Aigner A: MicroRNAs (miRNAs) in cancer
invasion and metastasis: Therapeutic approaches based on
metastasis-related miRNAs. J Mol Med (Berl). 89:445–457. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rottiers V and Näär AM: MicroRNAs in
metabolism and metabolic disorders. Nat Rev Mol Cell Biol.
13:239–250. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cho WC: MicroRNAs: Potential biomarkers
for cancer diagnosis, prognosis and targets for therapy. Int J
Biochem Cell Biol. 42:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang L, Chang L, Li Z, Gao Q, Cai D, Tian
Y, Zeng L and Li M: miR-99a and −99b inhibit cervical cancer cell
proliferation and invasion by targeting mTOR signaling pathway. Med
Oncol. 31:9342014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Croce CM and Calin GA: miRNAs, cancer, and
stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Babashah S and Soleimani M: The oncogenic
and tumour suppressive roles of microRNAs in cancer and apoptosis.
Eur J Cancer. 47:1127–1137. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
de Freitas AC, Gomes Leitão Mda C and
Coimbra EC: Prospects of molecularly-targeted therapies for
cervical cancer treatment. Curr Drug Targets. 16:77–91. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sun JY, Xiao WZ, Wang F, Wang YQ, Zhu YH,
Wu YF, Miao ZL and Lin YC: MicroRNA-320 inhibits cell proliferation
in glioma by targeting E2F1. Mol Med Rep. 12:2355–2359.
2015.PubMed/NCBI
|
|
27
|
Cheng C, Chen ZQ and Shi XT: MicroRNA-320
inhibits osteosarcoma cells proliferation by directly targeting
fatty acid synthase. Tumour Biol. 35:4177–4183. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu YY, Chen YL, Jao YC, Hsieh IS, Chang KC
and Hong TM: miR-320 regulates tumor angiogenesis driven by
vascular endothelial cells in oral cancer by silencing neuropilin
1. Angiogenesis. 17:247–260. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hsieh IS, Chang KC, Tsai YT, Ke JY, Lu PJ,
Lee KH, Yeh SD, Hong TM and Chen YL: MicroRNA-320 suppresses the
stem cell-like characteristics of prostate cancer cells by
downregulating the Wnt/beta-catenin signaling pathway.
Carcinogenesis. 34:530–538. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Siciliano V, Garzilli I, Fracassi C,
Criscuolo S, Ventre S and di Bernardo D: MiRNAs confer phenotypic
robustness to gene networks by suppressing biological noise. Nat
Commun. 4:23642013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kaestner KH, Knochel W and Martinez DE:
Unified nomenclature for the winged helix/forkhead transcription
factors. Genes Dev. 14:142–146. 2000.PubMed/NCBI
|
|
32
|
Koo CY, Muir KW and Lam EW: FOXM1: From
cancer initiation to progression and treatment. Biochim Biophys
Acta. 1819:28–37. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
He SY, Shen HW, Xu L, Zhao XH, Yuan L, Niu
G, You ZS and Yao SZ: FOXM1 promotes tumor cell invasion and
correlates with poor prognosis in early-stage cervical cancer.
Gynecol Oncol. 127:601–610. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hou Y, Li W, Sheng Y, Li L, Huang Y, Zhang
Z, Zhu T, Peace D, Quigley JG, Wu W, et al: The transcription
factor Foxm1 is essential for the quiescence and maintenance of
hematopoietic stem cells. Nat Immunol. 16:810–818. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chan DW, Yu SY, Chiu PM, Yao KM, Liu VW,
Cheung AN and Ngan HY: Over-expression of FOXM1 transcription
factor is associated with cervical cancer progression and
pathogenesis. J Pathol. 215:245–252. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen H, Zou Y, Yang H, Wang J and Pan H:
Downregulation of FoxM1 inhibits proliferation, invasion and
angiogenesis of HeLa cells in vitro and in vivo. Int
J Oncol. 45:2355–2364. 2014.PubMed/NCBI
|
